Biosimilar Resource Center

Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review

Healthcare resource utilization (HRU) increases in patients with non-medical switching (NMS) from biologic originators to their biosimilars


Biosimilars: A Value Proposition

The emergence of biosimilars in the marketplace promotes economic stability and enhances patient access to biological therapies while also providing more than economic benefits

Management of Cancer-Associated Anemia with Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

The use of erythropoiesis-stimulating agents (ESAs) including biosimilars can be administered to patients with non-curative cancer and chemotherapy-associated anemia, according to a study published in Journal of Clinical Oncology.

Population Pharmacokinetics of PF-05280014 (A Trastuzumab Biosimilar) and Reference Trastuzumab (Herceptin®) in Patients with...

The biosimilar to trastuzumab, PF-05280014, possesses similar pharmacokinetic (PK) parameters and covariates in Japanese patients with HER2-positive metastatic breast cancer (mBC), according to a study published in Cancer Chemotherapy and Pharmacology.

Perception of Hematologists and Oncologists About Biosimilars: A Prospective Tunisian Study Based on a...

A study published in Journal of Oncology Pharmacy Practice suggests that hematologists and oncologists in Tunisia lack knowledge on biosimilars and require enhanced training programs from health authorities.

Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and...

Evidence suggests that biosimilars and both safe and effective for use in oncology, according to the results of a recent study published in Bio Drugs.

Biosimilars in the Americas: The Future by Consensus

As biologics, biosimilars, and biomimics continue to emerge in Latin American countries, there remain regulatory inconsistencies on how these products should be tested and tendered in the management of rheumatic diseases. This prompted the Pan American League of Associations for Rheumatology (PANLAR) to develop a consensus statement on the matter, which was discussed in a review published in Clinical Rheumatology.

Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: Overview of the Literature and...

Switching from the originator infliximab (IFX-O) to its biosimilar (IXF-B) is acceptable in patients with inflammatory bowel disease (IBD), according to a study published in Therapeutic Advances in Gastroenterology.